{"count": 8, "results": [{"_id": "21291724", "pmid": 21291724, "title": "Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) study.", "journal": "J Clin Lipidol", "authors": ["Ballantyne CM", "Davidson MH", "McKenney JM", "Keller LH", "Bajorunas DR", "Karas RH"], "date": "2008-04-01T00:00:00Z", "doi": "10.1016/j.jacl.2008.02.004", "meta_date_publication": "2008 Apr", "meta_volume": "2", "meta_issue": "2", "meta_pages": "79-90", "score": 50076.96, "text_hl": "Treatment with both doses of NER/S was well tolerated; 59% of @SPECIES_9606 @@@patients@@@ experienced @<m>DISEASE_Flushing</m> @DISEASE_MESH:D005483 @@@flushing@@@, 78% of @<m>DISEASE_Flushing</m> @DISEASE_MESH:D005483 @@@flushing@@@ was mild or moderate in intensity, 49% of those who @<m>DISEASE_Flushing</m> @DISEASE_MESH:D005483 @@@flushed@@@ during dose titration did not @<m>DISEASE_Flushing</m> @DISEASE_MESH:D005483 @@@flush@@@ during weeks 13 to 24, and only 4.6% of @SPECIES_9606 @@@patients@@@ discontinued because of @<m>DISEASE_Flushing</m> @DISEASE_MESH:D005483 @@@flushing@@@. ", "citations": {"NLM": "Ballantyne CM, Davidson MH, McKenney JM, Keller LH, Bajorunas DR, Karas RH. Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) study. J Clin Lipidol. 2008 Apr;2(2):79-90. PMID: 21291724", "BibTeX": "@article{21291724, title={Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) study.}, author={Ballantyne CM and Davidson MH and McKenney JM and Keller LH and Bajorunas DR and Karas RH}, journal={J Clin Lipidol}, volume={2}, number={2}, pages={79-90}}"}}, {"_id": "19436666", "pmid": 19436666, "pmcid": "PMC2672455", "title": "Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin", "journal": "Vasc Health Risk Manag", "authors": ["Robinson JG"], "date": "2009-01-01T00:00:00Z", "doi": "10.2147/vhrm.s3190", "meta_date_publication": "2009", "meta_volume": "5", "meta_issue": "1", "meta_pages": "31-43", "score": 50069.062, "text_hl": "ER @CHEMICAL_Niacin @CHEMICAL_MESH:D009525 @@@niacin@@@-@<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ is reasonably well tolerated, with a <7% discontinuation rate due to @<m>DISEASE_Flushing</m> @DISEASE_MESH:D005483 @@@flushing@@@ in @SPECIES_9606 @@@patients@@@ who used @CHEMICAL_Aspirin @CHEMICAL_MESH:D001241 @@@aspirin@@@ or non-steroidal anti-inflammatory medications as needed. ", "citations": {"NLM": "Robinson JG. Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin Vasc Health Risk Manag. 2009;5(1):31-43. PMID: 19436666", "BibTeX": "@article{19436666, title={Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin}, author={Robinson JG}, journal={Vasc Health Risk Manag}, volume={5}, number={1}, pages={31-43}}"}}, {"_id": "20141348", "pmid": 20141348, "title": "A new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin + simvastatin.", "journal": "Expert Opin Investig Drugs", "authors": ["Yiu KH", "Cheung BM", "Tse HF"], "date": "2010-03-01T00:00:00Z", "doi": "10.1517/13543781003623223", "meta_date_publication": "2010 Mar", "meta_volume": "19", "meta_issue": "3", "meta_pages": "437-49", "score": 50067.21, "text_hl": "TAKE HOME MESSAGE: The triple combination therapy of @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@/ER @CHEMICAL_Niacin @CHEMICAL_MESH:D009525 @@@niacin@@@/@CHEMICAL_MK_0524 @CHEMICAL_MESH:C518174 @@@laropiprant@@@ may reduce @<m>DISEASE_Flushing</m> @DISEASE_MESH:D005483 @@@flushing@@@ side effects and facilitate a more comprehensive treatment for @SPECIES_9606 @@@patients@@@ with mixed @DISEASE_Dyslipidemias @DISEASE_MESH:D050171 @@@dyslipidemia@@@.", "citations": {"NLM": "Yiu KH, Cheung BM, Tse HF. A new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin + simvastatin. Expert Opin Investig Drugs. 2010 Mar;19(3):437-49. PMID: 20141348", "BibTeX": "@article{20141348, title={A new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin + simvastatin.}, author={Yiu KH and Cheung BM and Tse HF}, journal={Expert Opin Investig Drugs}, volume={19}, number={3}, pages={437-49}}"}}, {"_id": "20948500", "pmid": 20948500, "title": "Effects of low-dose of niacin associated to simvastatin in the treatment of mixed dyslipidemia Salgad.", "journal": "Minerva Cardioangiol", "authors": ["Salgado BJ", "Salgado JV", "Dos Santos AM", "Casulari LA"], "date": "2010-10-01T00:00:00Z", "meta_date_publication": "2010 Oct", "meta_volume": "58", "meta_issue": "5", "meta_pages": "531-42", "score": 50062.156, "text_hl": "There was low frequency of @<m>DISEASE_Flushing</m> @DISEASE_MESH:D005483 @@@flushing@@@ (10%) and no worsening in the control of fasting and postprandial glycemia and glycated hemoglobin. ", "citations": {"NLM": "Salgado BJ, Salgado JV, Dos Santos AM, Casulari LA. Effects of low-dose of niacin associated to simvastatin in the treatment of mixed dyslipidemia Salgad. Minerva Cardioangiol. 2010 Oct;58(5):531-42. PMID: 20948500", "BibTeX": "@article{20948500, title={Effects of low-dose of niacin associated to simvastatin in the treatment of mixed dyslipidemia Salgad.}, author={Salgado BJ and Salgado JV and Dos Santos AM and Casulari LA}, journal={Minerva Cardioangiol}, volume={58}, number={5}, pages={531-42}}"}}, {"_id": "18973399", "pmid": 18973399, "title": "Niacin extended-release/simvastatin.", "journal": "Drugs", "authors": ["Sanford M", "Curran MP"], "date": "2008-01-01T00:00:00Z", "doi": "10.2165/0003495-200868160-00008", "meta_date_publication": "2008", "meta_volume": "68", "meta_issue": "16", "meta_pages": "2373-86", "score": 50052.76, "text_hl": "@CHEMICAL_Niacin @CHEMICAL_MESH:D009525 @@@Niacin ER@@@/@<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ was generally well tolerated, with @<m>DISEASE_Flushing</m> @DISEASE_MESH:D005483 @@@flushing@@@ being the most common adverse reaction.", "citations": {"NLM": "Sanford M, Curran MP. Niacin extended-release/simvastatin. Drugs. 2008;68(16):2373-86. PMID: 18973399", "BibTeX": "@article{18973399, title={Niacin extended-release/simvastatin.}, author={Sanford M and Curran MP}, journal={Drugs}, volume={68}, number={16}, pages={2373-86}}"}}, {"_id": "19678716", "pmid": 19678716, "title": "Extended-release niacin (nicotinic acid)/laropiprant.", "journal": "Drugs", "authors": ["Perry CM"], "date": "2009-08-20T00:00:00Z", "doi": "10.2165/11203730-000000000-00000", "meta_date_publication": "2009 Aug 20", "meta_volume": "69", "meta_issue": "12", "meta_pages": "1665-79", "score": 50051.918, "text_hl": "@CHEMICAL_Niacin @CHEMICAL_MESH:D009525 @@@Niacin@@@ (@CHEMICAL_Niacinamide @CHEMICAL_MESH:D009536 @@@vitamin B3@@@) is a @CHEMICAL_Lipids @CHEMICAL_MESH:D008055 @@@lipid@@@-modifying drug and @CHEMICAL_MK_0524 @CHEMICAL_MESH:C518174 @@@laropiprant@@@ is an anti-@<m>DISEASE_Flushing</m> @DISEASE_MESH:D005483 @@@flushing@@@ agent, which reduces @<m>DISEASE_Flushing</m> @DISEASE_MESH:D005483 @@@flushing@@@ induced by @CHEMICAL_Niacin @CHEMICAL_MESH:D009525 @@@niacin@@@. ", "citations": {"NLM": "Perry CM. Extended-release niacin (nicotinic acid)/laropiprant. Drugs. 2009 Aug 20;69(12):1665-79. PMID: 19678716", "BibTeX": "@article{19678716, title={Extended-release niacin (nicotinic acid)/laropiprant.}, author={Perry CM}, journal={Drugs}, volume={69}, number={12}, pages={1665-79}}"}}, {"_id": "14759379", "pmid": 14759379, "title": "Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study).", "journal": "Am J Cardiol", "authors": ["Zhao XQ", "Morse JS", "Dowdy AA", "Heise N", "DeAngelis D", "Frohlich J", "Chait A", "Albers JJ", "Brown BG"], "date": "2004-02-01T00:00:00Z", "doi": "10.1016/j.amjcard.2003.10.009", "meta_date_publication": "2004 Feb 1", "meta_volume": "93", "meta_issue": "3", "meta_pages": "307-12", "score": 50045.2, "text_hl": "@SPECIES_9606 @@@Patients@@@ who received @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ plus @CHEMICAL_Niacin @CHEMICAL_MESH:D009525 @@@niacin@@@ and those on placebo had similar frequencies of clinical or laboratory side effects: any degree of @<m>DISEASE_Flushing</m> @DISEASE_MESH:D005483 @@@flushing@@@ (30% vs 23%, p = NS), symptoms of @DISEASE_Fatigue @DISEASE_MESH:D005221 @@@fatigue@@@, @DISEASE_Nausea @DISEASE_MESH:D009325 @@@nausea@@@, and/or @DISEASE_Myalgia @DISEASE_MESH:D063806 @@@muscle aches@@@ (9% vs 5%, p = NS), aspartate aminotransferase (SGOT) > or =3 times upper limit of normal (3% vs 1%, p = NS), CPK > or =2 times upper limit of normal (3% vs 4%, p = NS), CPK > or =5 times upper limit of normal, new onset of @CHEMICAL_Uric_Acid @CHEMICAL_MESH:D014527 @@@uric acid@@@ > or =7.5 mg/dl (18% vs 15%, p = NS), and @CHEMICAL_Homocysteine @CHEMICAL_MESH:D006710 @@@homocysteine@@@ > or =15 micromol/L (9% vs 4%, p = NS). ", "citations": {"NLM": "Zhao XQ, Morse JS, Dowdy AA, Heise N, DeAngelis D, Frohlich J, Chait A, Albers JJ, Brown BG. Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study). Am J Cardiol. 2004 Feb 1;93(3):307-12. PMID: 14759379", "BibTeX": "@article{14759379, title={Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study).}, author={Zhao XQ and Morse JS and Dowdy AA and Heise N and DeAngelis D and Frohlich J and Chait A and Albers JJ and Brown BG}, journal={Am J Cardiol}, volume={93}, number={3}, pages={307-12}}"}}, {"_id": "19574922", "pmid": 19574922, "title": "Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels.", "journal": "Curr Opin Cardiol", "authors": ["Hausenloy DJ", "Yellon DM"], "date": "2009-09-01T00:00:00Z", "doi": "10.1097/HCO.0b013e32832ebfe7", "meta_date_publication": "2009 Sep", "meta_volume": "24", "meta_issue": "5", "meta_pages": "473-82", "score": 50038.117, "text_hl": "Extended-release @CHEMICAL_Niacin @CHEMICAL_MESH:D009525 @@@nicotinic acid@@@ (or @CHEMICAL_Niacin @CHEMICAL_MESH:D009525 @@@Niacin@@@) remains the most effective pharmacological treatment currently available for elevating HDL-C, having recently been combined with @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ (as @CHEMICAL_Simcor @CHEMICAL_MESH:C562297 @@@Simcor@@@) and laropripant (as @CHEMICAL_MK_0524 @CHEMICAL_MESH:C518174 @@@Cordaptive@@@, to reduce @<m>DISEASE_Flushing</m> @DISEASE_MESH:D005483 @@@flushing@@@). ", "citations": {"NLM": "Hausenloy DJ, Yellon DM. Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels. Curr Opin Cardiol. 2009 Sep;24(5):473-82. PMID: 19574922", "BibTeX": "@article{19574922, title={Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels.}, author={Hausenloy DJ and Yellon DM}, journal={Curr Opin Cardiol}, volume={24}, number={5}, pages={473-82}}"}}]}